Third Party Review Organization Performance Report

Table of Contents


Introduction and Review Timeline Description	2
Definitions	
Names of Third Party Review Organizations	6
Third Party Performance Data	7
Initial Third Party Review Time – FY 2018	7
Third Party Hold Time – FY 2018	8
Total Third Party Review Time – FY 2018	9
Total FDA Review Time – FY 2018	10
Total Time to Decision from FDA Receipt – FY 2018	11
Total Time to Decision from Third Party Receipt – FY 2018	12
All Third Party Review Organizations	13
AABB	15
Center for Measurement Standards of Industrial (CMSI)	16
New York State Department of Health (NYSDOH)	17
Nordic Institute of Dental Materials (NIOM)	18
Regulatory Technology Services, LLC (RTS)	19
Third Party Review Group, LLC (TPRG)	21
TUV SUD America Inc. (TUV)	23

Introduction and Review Timeline Description

The Accredited Persons Program was created by the FDA Modernization Act of 1997 (FDAMA) to improve the efficiency and timeliness of FDA's 510(k) process. Under the program, FDA accredits Third Parties (Accredited Persons) that are authorized to conduct the primary review of 510(k)s for eligible devices. Under MDUFA IV, the FDA committed to publishing the performance of individual accredited Third Parties with at least five completed submissions on the Web (e.g., average number of holds, average time to final decision). A summary of Third Party Performance Metrics will be posted on a quarterly basis. This report contains data from FY 2018, Q1 through Q3 (October 1, 2017 through June 30, 2018). At this time, there are two Third Party Review Organizations with at least 5 completed submissions.

A Third Party 510(k) submission goes through four different stages before a final decision is made by FDA.

- Stage A The Third Party receives the file from the 510(k) Submitter, reviews the file, and sends the file and its decision recommendation to FDA.
- Stage B FDA reviews the submission to ensure that the Third Party has submitted all the information needed to make a final decision. If more information is needed, FDA makes a request of additional information, notifies the Third Party, and puts the submission on hold.
- Stage C (Optional) The Third Party reviews FDA's request for additional information and notifies the 510(k) submitter. The Third Party responds to FDA's deficiencies, updating the review memo and submission as necessary. The submission is considered on hold until FDA receives a complete response to its request for additional information.
- Stage D FDA reviews the additional information and makes a final decision.



- 1) Initial Third Party Review Time = A
- 2) Third Party Hold Time = C*
- 3) Total Third Party Review Time = A + C
- 4) Total FDA Review Time = B + D
- 5) Total Time to Decision from FDA Receipt = B + C + D
- 6) Total Time to Decision from Third Party Receipt = A + B + C + D

^{*}This data may not be present for all third party submissions.

Definitions

1) Initial Third Party Review Time:

- = Date FDA receives Third Party submission
- Date Third Party receives the file from the 510(k) Submitter

Elapsed time in days for the Third Party to review the 510(k) Submitter's file and determine its decision recommendation. The elapsed time includes the time needed for the 510(k) Submitter to resolve deficiencies. The Third Party provides the Submitter's file, its associated Third Party review documentation and its decision recommendation to FDA.

2) Third Party Hold Time:

- = Date FDA receives response to request for additional information
- Date FDA makes decision to put submission on hold

Elapsed time in days for the Third Party to respond to a request for additional information from FDA. If the Third Party does not receive a request for additional information, *Third Party Hold Time* is set to 0 days. If the file is placed on hold more than once, this is the total number of days the file has been on hold.

3) Total Third Party Review Time:

= Initial Third Party Review Time + Third Party Hold Time

Elapsed time in days for a Third Party to review a file from a 510(k) Submitter, including the time it is on hold.

4) Total FDA Review Time:

- = Date FDA makes Final Decision Date FDA receives Third Party Submission
- Third Party Hold Time

Elapsed time in days for FDA to provide a final MDUFA IV decision (SE or NSE) to a Third Party submission. By statute, FDA must provide a final MDUFA IV decision in 30 days. *Total FDA Review Time* does not include the number of days that a submission is on hold waiting for additional information from the Third Party.

5) Total Time to Decision from FDA Receipt:

= Total FDA Review Time + Third Party Hold Time

Elapsed time in days between FDA's receipt of a Third Party submission and FDA's final MDUFA IV decision. *Total Time to Decision from FDA Receipt* includes *Third Party Hold Time*, while *Total FDA Review Time* does not. For non-Third Party files, *Total Time to Decision from FDA Receipt* is called Total Time to Decision (TTD).

6) Total Time to Decision from Third Party Receipt:

= Total Third Party Review Time + Total FDA Review Time

Elapsed time in days for FDA and a Third Party to provide a final MDUFA IV decision to a submitter. *Total Time to Decision from Third Party Receipt* spans the entire lifecycle of a TP submission.

Names of Third Party Review Organizations

All 3PROs: All Third Party Review Organizations

AABB

CMSI: Center for Measurement Standards of Industrial

NYSDOH: New York State Department of Health

NIOM: Nordic Institute of Dental Materials RTS: Regulatory Technology Services, LLC TPRG: Third Party Review Group, LLC

TUV: TUV SUD America Inc.

Third Party Performance Data

Initial Third Party Review Time – FY 2018




Figure 1. Initial Third Party Review Time.

Third Party Hold Time - FY 2018




Figure 2. Third Party Hold Time.

Total Third Party Review Time - FY 2018




Figure 3. Total Third Party Review Time.

Total FDA Review Time - FY 2018




Figure 4. Total FDA Review Time.

Total Time to Decision from FDA Receipt – FY 2018




Figure 5. Total Time to Decision from FDA Receipt.

Total Time to Decision from Third Party Receipt – FY 2018




Figure 6. Total Time to Decision from Third Party Receipt.

All Third Party Review Organizations

Table 1.1. All: Third Party 510(k) MDUFA IV Decision Performance Goals.

Performance Metric	FY2018
Total Third Party 510(k) Submissions Accepted	53
Non-MDUFA IV Final Decisions: Withdrawn or Deleted (%)	1 (2%)
MDUFA IV Final Decisions: SE or NSE (%)	38 (72%)
Pending Final Decision for less than 30 FDA days (%)	14 (26%)
Pending Final Decision for more than 30 FDA days (%)	0 (0%)
Current Performance: Third Party Submissions that received MDUFA IV Final Decisions (SE or NSE) within 30 FDA Days (%)	90%
Average Holds	
Third Party Submission with a Final Decision	39
Total # Requests for Additional Information (Holds)	20
Average # Requests for Additional Information per Submission	0.51
Third Party Recommendation and Final Decision Agreement	
Third Party Submissions with a Final Decision	39
Third Party SE Recommendations	39 (100%)
Third Party NSE Recommendations	0 (0%)
Third Party SE Recommendations with a Final Decision	39
MDUFA IV Final Decision	
SE	38 (97%)
NSE	0 (0%)
Non-MDUFA IV Final Decision	
Withdrawn	0 (0%)
Deleted	1 (3%)
Third Party NSE Recommendations with a Final Decision MDUFA IV Final Decision	0
SE	0 (0%)
NSE	0 (0%)
Non-MDUFA IV Final Decision	, ,
Withdrawn	0 (0%)
Deleted	0 (0%)

Table 1.2. All: Third Party 510(k) Review Time Performance Metrics.

Performance Metric	FY2018
Average Initial Third Party Review Time (Calendar Days)	65
25th Percentile Initial Third Party Review Time	26
50th Percentile Initial Third Party Review Time	41
75th Percentile Initial Third Party Review Time	80
Maximum Initial Third Party Review Time	397
Average Third Party Hold Time (Calendar Days)	18
25th Percentile Third Party Hold Time	0
50th Percentile Third Party Hold Time	3
75th Percentile Third Party Hold Time	21
Maximum Third Party Hold Time	118
Average Total Third Party Review Time (Calendar Days)	82
25th Percentile Total Third Party Review Time	33
50th Percentile Total Third Party Review Time	55
75th Percentile Total Third Party Review Time	115
Maximum Total Third Party Review Time	397
Average Total FDA Review Time (Calendar Days)	28
25th Percentile Total FDA Review Time	24
50th Percentile Total FDA Review Time	28
75th Percentile Total FDA Review Time	30
Maximum Total FDA Review Time	68
Average Total Time to Decision from FDA Receipt (Calendar Days)	45
25th Percentile Total TTD from FDA Receipt	26
50th Percentile Total TTD from FDA Receipt	30
75th Percentile Total TTD from FDA Receipt	49
Maximum Cumulative TTD from FDA Receipt Date	154
Average Total Time to Decision from Third Party Receipt (Calendar Days)	110
25th Percentile Total TTD from Third Party Receipt	54
50th Percentile Total TTD from Third Party Receipt	82
75th Percentile Total TTD from Third Party Receipt	142
Maximum Total TTD from Third Party Receipt	410

AABB

Center for Measurement Standards of Industrial (CMSI)

New York State Department of Health (NYSDOH)

Nordic Institute of Dental Materials (NIOM)

Regulatory Technology Services, LLC (RTS)

Table 2.1. RTS: Third Party 510(k) MDUFA IV Decision Performance Goals. Regulatory Technology Services, LLC (RTS).

Performance Metric	FY2018
Total Third Party 510(k) Submissions Accepted	36
Non-MDUFA IV Final Decisions: Withdrawn or Deleted (%)	0 (0%)
MDUFA IV Final Decisions: SE or NSE (%)	28 (78%)
Pending Final Decision for less than 30 FDA days (%)	8 (22%)
Pending Final Decision for more than 30 FDA days (%)	0 (0%)
Current Performance: Third Party Submissions that received MDUFA IV Final Decisions (SE or NSE) within 30 FDA Days (%)	93%
Average Holds	
Third Party Submission with a Final Decision	28
Total # Requests for Additional Information (Holds)	13
Average # Requests for Additional Information per Submission	0.46
Third Party Recommendation and Final Decision Agreement	
Third Party Submissions with a Final Decision	28
Third Party SE Recommendations	28 (100%)
Third Party NSE Recommendations	0 (0%)
Third Party SE Recommendations with a Final Decision MDUFA IV Final Decision	28
SE	28 (100%)
NSE	0 (0%)
Non-MDUFA IV Final Decision	,
Withdrawn	0 (0%)
Deleted	0 (0%)
Third Party NSE Recommendations with a Final Decision	0
MDUFA IV Final Decision	· ·
SE	0 (0%)
NSE	0 (0%)
Non-MDUFA IV Final Decision	, ,
Withdrawn	0 (0%)
Deleted	0 (0%)

Table 2.2. RTS: Third Party 510(k) Review Time Performance Metrics. Regulatory Technology Services, LLC (RTS).

Performance Metric	FY2018
Average Initial Third Party Review Time (Calendar Days)	64
25th Percentile Initial Third Party Review Time	29
50th Percentile Initial Third Party Review Time	41
75th Percentile Initial Third Party Review Time	73
Maximum Initial Third Party Review Time	397
Average Third Party Hold Time (Calendar Days)	11
25th Percentile Third Party Hold Time	0
50th Percentile Third Party Hold Time	0
75th Percentile Third Party Hold Time	12
Maximum Third Party Hold Time	116
Average Total Third Party Review Time (Calendar Days)	74
25th Percentile Total Third Party Review Time	29
50th Percentile Total Third Party Review Time	54
75th Percentile Total Third Party Review Time	91
Maximum Total Third Party Review Time	397
Average Total FDA Review Time (Calendar Days)	27
25th Percentile Total FDA Review Time	23
50th Percentile Total FDA Review Time	27
75th Percentile Total FDA Review Time	30
Maximum Total FDA Review Time	68
Average Total Time to Decision from FDA Receipt (Calendar Days)	38
25th Percentile Total TTD from FDA Receipt	25
50th Percentile Total TTD from FDA Receipt	30
75th Percentile Total TTD from FDA Receipt	37
Maximum Cumulative TTD from FDA Receipt Date	149
Average Total Time to Decision from Third Party Receipt (Calendar Days)	101
25th Percentile Total TTD from Third Party Receipt	53
50th Percentile Total TTD from Third Party Receipt	80
75th Percentile Total TTD from Third Party Receipt	126
Maximum Total TTD from Third Party Receipt	410

Third Party Review Group, LLC (TPRG)

Table 3.1. TPRG: Third Party 510(k) MDUFA IV Decision Performance Goals. Third Party Review Group, LLC (TPRG).

Total Third Party 510(k) Submissions Accepted 13 Non-MDUFA IV Final Decisions: Withdrawn or Deleted (%) 1 (8%) MDUFA IV Final Decisions: SE or NSE (%) 7 (54%) Pending Final Decision for less than 30 FDA days (%) 5 (38%) Pending Final Decision for more than 30 FDA days (%) 0 (0%) Current Performance: Third Party Submissions that received MDUFA IV Final Decisions (SE or NSE) within 30 FDA Days (%) 86% Final Decisions (SE or NSE) within 30 FDA Days (%) Warage Holds Third Party Submission with a Final Decision 8 Total # Requests for Additional Information (Holds) 5 Average # Requests for Additional Information per Submission 0.62 Third Party Recommendation and Final Decision Agreement Third Party SE Recommendations 8 (100%) Third Party SE Recommendations 8 (100%) Third Party NSE Recommendations 8 (100%) Third Party SE Recommendations with a Final Decision 8 MDUFA IV Final Decision SE 7 (88%) NSE 0 (0%) Non-MDUFA IV Final Decision Withdrawn Deleted 1 (12%) Third Party NSE Recommendations with a Final Decision SE 0 (0%) NDIFA IV Final Decision SE 0 (0%) NSE 0 (0%) NOn-MDUFA IV Final Decision Withdrawn 0 (0%) NSE NSE 0 (0%) NOn-MDUFA IV Final Decision Withdrawn 0 (0%) NSE NSE 0 (0%) NSE NSE 0 (0%) NSE 0	Performance Metric	FY2018
MDUFA IV Final Decisions: SE or NSE (%) 7 (54%) Pending Final Decision for less than 30 FDA days (%) 5 (38%) Pending Final Decision for more than 30 FDA days (%) 0 (0%) Current Performance: Third Party Submissions that received MDUFA IV Final Decisions (SE or NSE) within 30 FDA Days (%) 86% Average Holds Third Party Submission with a Final Decision 8 Total # Requests for Additional Information (Holds) 5 Average # Requests for Additional Information per Submission 0.62 Third Party Recommendation and Final Decision Agreement 8 Third Party Submissions with a Final Decision Agreement 8 Third Party NSE Recommendations 0 (0%) Third Party NSE Recommendations with a Final Decision 8 MDUFA IV Final Decision 8 NSE 0 (0%) Non-MDUFA IV Final Decision 0 (0%) Withdrawn 0 (0%) Deleted 1 (12%) Third Party NSE Recommendations with a Final Decision 0 Withdrawn 0 (0%) NSE 0 (0%) NSE 0 (0%) NSE 0 (0%) <t< td=""><td>Total Third Party 510(k) Submissions Accepted</td><td>13</td></t<>	Total Third Party 510(k) Submissions Accepted	13
Pending Final Decision for less than 30 FDA days (%) 5 (38%) Pending Final Decision for more than 30 FDA days (%) 0 (0%) Current Performance: Third Party Submissions that received MDUFA IV Final Decisions (SE or NSE) within 30 FDA Days (%) Average Holds Third Party Submission with a Final Decision 8 8 7	Non-MDUFA IV Final Decisions: Withdrawn or Deleted (%)	1 (8%)
Pending Final Decision for more than 30 FDA days (%) 0 (0%) Current Performance: Third Party Submissions that received MDUFA IV Final Decisions (SE or NSE) within 30 FDA Days (%) Average Holds Third Party Submission with a Final Decision 8 Average # Requests for Additional Information (Holds) 5 Average # Requests for Additional Information per Submission 0.62 Third Party Recommendation and Final Decision Agreement Third Party Submissions with a Final Decision Agreement Third Party SE Recommendations 8 (100%) Third Party NSE Recommendations 0 (0%) Third Party SE Recommendations with a Final Decision 8 MDUFA IV Final Decision SE 7 (88%) NSE 0 (0%) Non-MDUFA IV Final Decision Withdrawn 0 (0%) Deleted 1 (12%) Third Party NSE Recommendations with a Final Decision 0 MDUFA IV Final Decision SE 0 (0%) NSE 0 (0%) NOn-MDUFA IV Final Decision 0 (0%) NSE 0 (0%) NSE 0 (0%) NON-MDUFA IV Final Decision 0 (0%) NSE 0 (0%) NON-MDUFA IV Final Decision 0 (0%) NON-MDUFA IV Final Decision 0 (0%) NSE 0 (0%) NON-MDUFA IV Final Decision 0 (0%)	MDUFA IV Final Decisions: SE or NSE (%)	7 (54%)
Current Performance: Third Party Submissions that received MDUFA IV Final Decisions (SE or NSE) within 30 FDA Days (%) Average Holds Third Party Submission with a Final Decision Total # Requests for Additional Information (Holds) Average # Requests for Additional Information per Submission Third Party Recommendation and Final Decision Agreement Third Party Submissions with a Final Decision Third Party SE Recommendations Third Party NSE Recommendations Third Party NSE Recommendations Third Party SE Recommendations Third Party SE Recommendations with a Final Decision SE NSE NSE NSE O (0%) Non-MDUFA IV Final Decision Withdrawn Deleted Third Party NSE Recommendations with a Final Decision Withdrawn Deleted Third Party NSE Recommendations with a Final Decision SE NSE O (0%) Non-MDUFA IV Final Decision SE NSE O (0%) Non-MDUFA IV Final Decision SE O (0%) NSE O (0%) Non-MDUFA IV Final Decision SE O (0%) Non-MDUFA IV Final Decision SE O (0%) Non-MDUFA IV Final Decision Withdrawn O (0%)	Pending Final Decision for less than 30 FDA days (%)	5 (38%)
Final Decisions (SE or NSE) within 30 FDA Days (%) Average Holds Third Party Submission with a Final Decision	Pending Final Decision for more than 30 FDA days (%)	0 (0%)
Average Holds Third Party Submission with a Final Decision Total # Requests for Additional Information (Holds) Average # Requests for Additional Information per Submission Third Party Recommendation and Final Decision Agreement Third Party Submissions with a Final Decision Third Party SE Recommendations Third Party NSE Recommendations Third Party SE Recommendations Third Party SE Recommendations Third Party SE Recommendations with a Final Decision SE NSE NSE 0 (0%) Non-MDUFA IV Final Decision Withdrawn Deleted Third Party NSE Recommendations with a Final Decision Withdrawn Deleted Third Party NSE Recommendations with a Final Decision NDUFA IV Final Decision SE 0 (0%) Non-MDUFA IV Final Decision SE NSE 0 (0%) NSE NSE 0 (0%) NSE NOn-MDUFA IV Final Decision Withdrawn 0 (0%)		
Third Party Submission with a Final Decision Total # Requests for Additional Information (Holds) Average # Requests for Additional Information per Submission Third Party Recommendation and Final Decision Agreement Third Party Submissions with a Final Decision Third Party SE Recommendations Third Party NSE Recommendations Third Party NSE Recommendations Third Party SE Recommendations Third Party SE Recommendations with a Final Decision SE MDUFA IV Final Decision SE Non-MDUFA IV Final Decision Withdrawn Deleted Third Party NSE Recommendations with a Final Decision O (0%) Third Party NSE Recommendations with a Final Decision O (0%) Third Party NSE Recommendations with a Final Decision O (0%) Third Party NSE Recommendations with a Final Decision O (0%) NDUFA IV Final Decision SE O (0%) NSE O (0%) NOn-MDUFA IV Final Decision Withdrawn O (0%) Non-MDUFA IV Final Decision Withdrawn O (0%)	Average Holds	
Total # Requests for Additional Information (Holds) Average # Requests for Additional Information per Submission Third Party Recommendation and Final Decision Agreement Third Party Submissions with a Final Decision A third Party SE Recommendations A third Party NSE Recommendations A third Party SE Recommendations with a Final Decision A se third Party SE Recommendations with a Final Decision A se third Party NSE Recommendations with a Final Decision A se third Party NSE Recommendations with a Final Decision A se third Party NSE Recommendations A se third Party NSE Re	•	8
Third Party Recommendation and Final Decision Agreement Third Party Submissions with a Final Decision Third Party SE Recommendations Third Party NSE Recommendations O (0%) Third Party SE Recommendations with a Final Decision SE Recommendations NSE O (0%) Non-MDUFA IV Final Decision Withdrawn Deleted 1 (12%) Third Party NSE Recommendations with a Final Decision With Party NSE Recommendations with a Final Decision O (0%) NDUFA IV Final Decision SE O (0%) NDUFA IV Final Decision SE O (0%) NSE O (0%) NSE O (0%) NOn-MDUFA IV Final Decision Withdrawn O (0%) NON-MDUFA IV Final Decision Withdrawn O (0%)	•	5
Third Party Submissions with a Final Decision Third Party SE Recommendations Third Party NSE Recommendations Third Party SE Recommendations Third Party SE Recommendations with a Final Decision SE Recommendations with a Final Decision SE 7 (88%) NSE 0 (0%) Non-MDUFA IV Final Decision Withdrawn 0 (0%) Deleted 1 (12%) Third Party NSE Recommendations with a Final Decision MDUFA IV Final Decision SE 0 (0%) NSE 0 (0%) NSE 0 (0%) NSE 0 (0%) Non-MDUFA IV Final Decision Withdrawn 0 (0%) Non-MDUFA IV Final Decision Withdrawn 0 (0%)	Average # Requests for Additional Information per Submission	0.62
Third Party SE Recommendations Third Party NSE Recommendations Third Party SE Recommendations with a Final Decision SE 7 (88%) NSE 0 (0%) Non-MDUFA IV Final Decision Withdrawn 0 (0%) Deleted 1 (12%) Third Party NSE Recommendations with a Final Decision MDUFA IV Final Decision SE 0 (0%) Non-MDUFA IV Final Decision O (0%) Deleted 1 (12%)	Third Party Recommendation and Final Decision Agreement	
Third Party NSE Recommendations Third Party SE Recommendations with a Final Decision MDUFA IV Final Decision SE 7 (88%) NSE 0 (0%) Non-MDUFA IV Final Decision Withdrawn 0 (0%) Deleted Third Party NSE Recommendations with a Final Decision MDUFA IV Final Decision SE 0 (0%) NSE 0 (0%) NSE 0 (0%) NSE 0 (0%) NSE 0 (0%) Non-MDUFA IV Final Decision Withdrawn 0 (0%)	Third Party Submissions with a Final Decision	8
Third Party SE Recommendations with a Final Decision MDUFA IV Final Decision SE 7 (88%) NSE 0 (0%) Non-MDUFA IV Final Decision Withdrawn Deleted Third Party NSE Recommendations with a Final Decision MDUFA IV Final Decision SE 0 (0%) NSE 0 (0%) NSE 0 (0%) NSE 0 (0%) Non-MDUFA IV Final Decision Withdrawn 0 (0%) Non-MDUFA IV Final Decision Withdrawn 0 (0%)	Third Party SE Recommendations	8 (100%)
MDUFA IV Final Decision 7 (88%) SE 7 (0%) NSE 0 (0%) Non-MDUFA IV Final Decision 0 (0%) Withdrawn 0 (0%) Deleted 1 (12%) Third Party NSE Recommendations with a Final Decision 0 MDUFA IV Final Decision 0 (0%) NSE 0 (0%) Non-MDUFA IV Final Decision 0 (0%) Withdrawn 0 (0%)	Third Party NSE Recommendations	0 (0%)
SE 7 (88%) NSE 0 (0%) Non-MDUFA IV Final Decision 0 (0%) Withdrawn 0 (0%) Deleted 1 (12%) Third Party NSE Recommendations with a Final Decision 0 MDUFA IV Final Decision 0 (0%) NSE 0 (0%) Non-MDUFA IV Final Decision 0 (0%) Withdrawn 0 (0%)	•	8
Non-MDUFA IV Final Decision Withdrawn Deleted Third Party NSE Recommendations with a Final Decision MDUFA IV Final Decision SE NSE 0 (0%) NSE Non-MDUFA IV Final Decision Withdrawn O (0%)		7 (88%)
Withdrawn 0 (0%) Deleted 1 (12%) Third Party NSE Recommendations with a Final Decision 0 MDUFA IV Final Decision SE 0 (0%) NSE 0 (0%) Non-MDUFA IV Final Decision Withdrawn 0 (0%)	NSE	0 (0%)
Deleted 1 (12%) Third Party NSE Recommendations with a Final Decision 0 MDUFA IV Final Decision SE 0 (0%) NSE 0 (0%) Non-MDUFA IV Final Decision Withdrawn 0 (0%)	Non-MDUFA IV Final Decision	
Third Party NSE Recommendations with a Final Decision MDUFA IV Final Decision SE NSE Non-MDUFA IV Final Decision Withdrawn O (0%) O (0%)	Withdrawn	0 (0%)
MDUFA IV Final Decision SE 0 (0%) NSE 0 (0%) Non-MDUFA IV Final Decision Withdrawn 0 (0%)	Deleted	1 (12%)
NSE 0 (0%) Non-MDUFA IV Final Decision Withdrawn 0 (0%)	•	0
NSE Non-MDUFA IV Final Decision Withdrawn 0 (0%) 0 (0%)	SE	0 (0%)
Non-MDUFA IV Final Decision Withdrawn 0 (0%)	NSE	` ,
	Non-MDUFA IV Final Decision	, ,
· ,	Withdrawn	0 (0%)
	Deleted	0 (0%)

Table 3.2. TPRG: Third Party 510(k) Review Time Performance Metrics. Third Party Review Group, LLC (TPRG).

Performance Metric	FY2018
Average Initial Third Party Review Time (Calendar Days)	91
25th Percentile Initial Third Party Review Time	56
50th Percentile Initial Third Party Review Time	80
75th Percentile Initial Third Party Review Time	128
Maximum Initial Third Party Review Time	168
Average Third Party Hold Time (Calendar Days)	33
25th Percentile Third Party Hold Time	7
50th Percentile Third Party Hold Time	22
75th Percentile Third Party Hold Time	38
Maximum Third Party Hold Time	118
Average Total Third Party Review Time (Calendar Days)	124
25th Percentile Total Third Party Review Time	69
50th Percentile Total Third Party Review Time	137
75th Percentile Total Third Party Review Time	180
Maximum Total Third Party Review Time	198
Average Total FDA Review Time (Calendar Days)	30
25th Percentile Total FDA Review Time	27
50th Percentile Total FDA Review Time	29
75th Percentile Total FDA Review Time	30
Maximum Total FDA Review Time	41
Average Total Time to Decision from FDA Receipt (Calendar Days)	63
25th Percentile Total TTD from FDA Receipt	36
50th Percentile Total TTD from FDA Receipt	50
75th Percentile Total TTD from FDA Receipt	72
Maximum Cumulative TTD from FDA Receipt Date	147
Average Total Time to Decision from Third Party Receipt (Calendar Days)	154
25th Percentile Total TTD from Third Party Receipt	97
50th Percentile Total TTD from Third Party Receipt	161
75th Percentile Total TTD from Third Party Receipt	213
Maximum Total TTD from Third Party Receipt	231

TUV SUD America Inc. (TUV)